Search
N,N,N-trimethylglycinium
go.drugbank.com/drugs/DB04455InvestigationalAs a drug, betaine hydrochloride has been used as a source of hydrochloric acid in the treatment of hypochlorhydria. … A naturally occurring compound that has been of interest for its role in osmoregulation.
Amsilarotene
go.drugbank.com/drugs/DB21085InvestigationalAmsilarotene is a small molecule drug. The usage of the INN stem '-arotene' in the name indicates that Amsilarotene is a arotinoid derivative. … Amsilarotene has a monoisotopic molecular weight of 385.15 Da.
Medical Cannabis
go.drugbank.com/drugs/DB14009Investigationalisomer as [DB00470], or in a 1:1 formulation with CBD from purified plant extract as [DB14011]. … The use of the plant species _Cannabis sativa_ and _Cannabis indica_, popularly known as marijuana, has gained popularity in recent years for the management of a wide variety of medical conditions as a
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsRPI-78M
go.drugbank.com/drugs/DB05740ExperimentalRPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
NKX101
go.drugbank.com/drugs/DB18131InvestigationalNKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.
Synonyms: a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15NS-3728
go.drugbank.com/drugs/DB05835ExperimentalNS3728 is an orally active chloride channel blocker for the treatment of cancer.
Vadimezan
go.drugbank.com/drugs/DB06235InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalIn blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. … Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates